** Shares of Immuron IMC.AX rise as much as 1.2% to
A$0.088, their highest since June 27
** After market hours on Thursday, co received https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02539596-3A596834?access_token=83ff96335c2d45a094df02a206a39ff4
notification of an intent to grant a European patent for the
compositions and methods for co's treatment of a large intestine
disease caused by toxins produced by the bacterium
Clostridioides difficile
** The European registration, once formally granted, will
add to IMC's patent position for treatment of the disease in
Australia, New Zealand and the United States
** Stock down ~13% this year, as of last close
(Reporting by Upasana Singh in Bengaluru)
((Upasana.Singh@thomsonreuters.com))